KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to -$402.9 million.

  • Regeneron Pharmaceuticals' Cash from Investing Activities rose 29.86% to -$402.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$498.8 million, marking a year-over-year increase of 82.71%. This contributed to the annual value of -$2.5 billion for FY2024, which is 22.51% up from last year.
  • Regeneron Pharmaceuticals' Cash from Investing Activities amounted to -$402.9 million in Q3 2025, which was up 63.17% from -$1.1 billion recorded in Q2 2025.
  • Regeneron Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $647.5 million during Q1 2025, with a 5-year trough of -$2.4 billion in Q3 2021.
  • In the last 3 years, Regeneron Pharmaceuticals' Cash from Investing Activities had a median value of -$496.3 million in 2023 and averaged -$591.1 million.
  • Data for Regeneron Pharmaceuticals' Cash from Investing Activities shows a peak YoY increase of 629.61% (in 2024) and a maximum YoY decrease of 615.78% (in 2024) over the last 5 years.
  • Over the past 5 years, Regeneron Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at -$2.0 billion in 2021, then increased by 7.70% to -$1.9 billion in 2022, then skyrocketed by 96.44% to -$66.2 million in 2023, then spiked by 629.61% to $350.6 million in 2024, then climbed by 29.86% to -$402.9 million in 2025.
  • Its Cash from Investing Activities was -$402.9 million in Q3 2025, compared to -$1.1 billion in Q2 2025 and $647.5 million in Q1 2025.